Diabetes (type 2) - canagliflozin: evaluation report

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

Evaluation report:

01. NICE's response to comments on the Appraisal Consultation Document (ACD)

02. Consultee comments on the ACD - Association of British Clinical Diabetologists

03. Commentator comments on the ACD - AstraZeneca

04. Commentator comments on the ACD - Department of Health

05. Consultee comments on the ACD - Janssen

06. Commentator comments on the ACD - Lilly UK

07. Commentator comments on the ACD - Merck Sharp & Dohme

08. Commentator comments on the ACD - Novo Nordisk

09. Consultee comments on the ACD - Royal College of Physicians

10. Consultee comments on the ACD - Royal College of Nursing

This page was last updated: 14 May 2014